A Deep Dive Into TFOS DEWS II
A Deeper Dive Into Dry Eye Disease
by Bryn Mawr Communications
2y ago
Carolina Betancurt, OD, MBA, Medical Director of Ophthalmology, Ophthalmics, Novartis Pharmaceuticals Corporation speaks with Douglas K. Devries, OD, Co-founder of Eye Care Associates of Nevada about the key takeaways of the TFOS DEWS II report and how to incorporate it into your practice ..read more
Visit website
The Ocular Surface, Pathophysiology, and Subtypes of Dry Eye Disease
A Deeper Dive Into Dry Eye Disease
by Bryn Mawr Communications
2y ago
Carolina Betancurt, OD, MBA, Medical Director of Ophthalmology, Ophthalmics, Novartis Pharmaceuticals Corporation speaks with Douglas K. Devries, OD, Co-founder of Eye Care Associates of Nevada, and Christopher Starr, MD, from Weill Cornell Medicine in New York City about optimizing the ocular surface, implementing dry eye screening into your practice, and utilizing the TFOS DEWS II treatment algorithm ..read more
Visit website
A Deep Dive Into TFOS DEWS II
A Deeper Dive Into Dry Eye Disease
by Bryn Mawr Communications
3y ago
Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation, speaks with Scott Schachter, OD, from Advanced Eyecare and the Eyewear Gallery Optometry in Pismo Beach, California, about the key takeaways of the TFOS DEWS II report and how to incorporate it into your practice ..read more
Visit website
Preoperative Management of Ocular Surface Disease
A Deeper Dive Into Dry Eye Disease
by Bryn Mawr Communications
3y ago
Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation holds a discussion with Christopher Starr, MD, from Weill Cornell Medicine in New York City about visually and non-visually significant dry eye disease and managing a preoperative treatment course ..read more
Visit website
The Ocular Surface, Pathophysiology, and Subtypes of Dry Eye Disease
A Deeper Dive Into Dry Eye Disease
by Bryn Mawr Communications
3y ago
Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation speaks with Scott Schachter, OD, from Advanced Eyecare and the Eyewear Gallery Optometry in Pismo Beach, California, and Christopher Starr, MD, from Weill Cornell Medicine in New York City about optimizing the ocular surface, implementing dry eye screening into your practice, and utilizing the TFOS DEWS II treatment algorithm ..read more
Visit website
Modifiable and Non-Modifiable Risk Factors
A Deeper Dive Into Dry Eye Disease
by Bryn Mawr Communications
3y ago
Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation holds a conversation with Laura Periman, MD, from the Periman Eye Institute in Seattle, Washington, and Christopher Starr, MD, from Weill Cornell Medicine in New York City about how to categorize and manage modifiable and non-modifiable risk factors of dry eye disease ..read more
Visit website
Assessing Clinical Signs and Symptoms of Dry Eye Disease
A Deeper Dive Into Dry Eye Disease
by Bryn Mawr Communications
3y ago
and Leslie O'Dell, OD, from Medical Optometry America in York, Pennsylvania, discuss clinical signs and symptoms of dry eye disease, how dry eye disease affects patients’ corneal health, and options in testing and questionnaire use ..read more
Visit website

Follow A Deeper Dive Into Dry Eye Disease on FeedSpot

Continue with Google
Continue with Apple
OR